Research Updates

Overview: 

In 2019, ANZCHOG approached the Children's Tumour Foundation (CTF) to support its efforts to run a phase II MEK Inhibitor clinical trial across multiple paediatric and adolescent/young adult cancer centres in Australia and New Zealand.

This is the first Australian-led clinical trial of the MEK Inhibitor drug, Trametinib and the first NF research study to receive funding from the Australian Federal Government. The seven-year study will investigate the effectiveness of Trametinib for the treatment of plexiform neurofibromas and optic pathway gliomas. In addition to monitoring the expected reduction in tumour size, it will also monitor the improvement in pain, function, and quality of life, as well as brain function and social development.

For the past 18 months, the Children's Tumour Foundation has been advocating and raising funds to support the trial, which is expected to start enrolling patients as early as January 2021.

Once the trial is complete, the results will contribute to a body of evidence that supports making this drug affordable and available to anyone living with these specific tumour types as a front-line treatment, and not a last resort.

Current Status: Recruitment In Progress from January 2021

Eligibility Criteria:  Enrolments are expected to begin as early as January 2021 with for up to 60 patients from hospitals around the country and will occur directly through existing patient lists. To be eligible for the trial, a patient will need:

• to be aged between 3 months and 25 years when they start the trial
• to have NF1 
• to have an optic pathway glioma where the tumour has continued to grow or the vision tests have deteriorated after treatment such as chemotherapy; or
• to have a plexiform neurofibroma which is causing significant problems and where surgery is not an option. This could include symptoms like nerve pain, cosmetic issues, nerve or spinal compression and other problems. 

The team are also looking for volunteers with NF1 who do not have a plexiform NF or progressive OPG and therefore do not need treatment with Trametinib. These children will be asked to complete the same cognitive (learning) assessments as children receiving the medication to provide a comparison.

Hospitals involved in the study:

Source of Recruitment: NF Clinics / The CTF / Via Referral from any hospital

Treatment: Trametinib

Expected Timings :  starting January 2021

• Recruitment Duration: 2 Years
• Treatment Duration: 2 Years
• Follow-up Duration: 3 Years
• Total trial Duration: 7 Years

Contact Details for the Study: Karli | E: anzchog_tint@anzchog.org

Findings Available: No

Overview: 

Paediatric sleep problems are a common occurrence and are associated with significant daytime impairments. Paediatric sleep problems can present as the primary sleep disorder, as a secondary consequence of an underlying medical issue or as a psychiatric disorder. They can also compromise social, academic and neurobehavioural functioning. Evidence suggests an increase risk for sleep problems in children with NF1. 

This research study will characterise the sleep profile of children with NF1 utilising comprehensive sleep history and objective assessment. This work will provide novel insight into the frequency of sleep disturbances and sleep disorders and identify the biopsychosocial factors contributing to poor sleep in NF1. 

This study will also examine the impact of poor sleep on day-to-day functioning of children with NF1. Results from this study will be important for the design of future intervention studies and guide future patient management for sleep disturbance in children with NF1.

Current Status: Recruitment Commenced

Source of Recruitment: NF Clinics

Findings Available: No

Overview: 

Dopamine dysregulation has been identified as a key modulator of behavioural impairment in Neurofibromatosis Type 1 (NF1) and a potential therapeutic target. Preclinical research involving NF1 mouse models suggests methylphenidate, a stimulant medication that increases dopaminergic neurotransmission, rescues spatial-learning and attentional dysfunction. 

This randomised, double-blind placebo-controlled trial will assess the efficacy of methylphenidate for reducing attention deficits, spatial working memory impairments and ADHD symptoms in children with NF1

Treatment: Methylphenidate/placebo

Current Status: Recruitment Commenced

Source of Recruitment: NF Clinics / CTF (previous)

Findings Available: No

Overview: 

Reduced muscle tone, muscle weakness and fatigue can impact considerably on quality of life for children with Neurofibromatosis type 1 (NF1). Human muscle biopsies and mouse models of NF1 deficiency in muscle show intramyocellular lipid accumulation, and preclinical data has indicated that L-carnitine supplementation can ameliorate this phenotype. 

The goal of this study is to examine whether daily L-carnitine supplementation is safe and feasible, and will improve muscle strength and reduce fatigue in children with NF1.

Treatment: L-carnitine

Current Status: Recruitment complete, data analysis and publication

Source of Recruitment: NF Clinics / CTF (previous)

Findings Available: No

Overview: 

This research project aims to understand the different features of Neurofibromatosis type 1 (NF1) and to direct future research into this condition by inclusion of clinical data in a registry.

The team hope that by studying more people investigators will be able to better understand why this condition is so variable as well as allow for better diagnosis, predict the type or severity of problems people may have and allow for further research to find ways to prevent or treat them in the future.

The study will gather information from medical histories, family histories, scan results (ultrasound, CT and MRI) as required for clinical care, clinical examinations at the NF clinic and/or genetics clinic visits, clinical examination at ophthalmology clinic, neuropsychological test results and genetic test results as required for clinical care.

This study is planned to be ongoing for many years with the intention of collecting information from hunders of people of different ages with different features associated with NF1.

Current Status: Recruiting

Source of Recruitment: NF Clinic, Melbourne

Findings Available: No

Overview: 

Recent evidence suggests that 1 in every 4 children with NF1 has autism spectrum disorder. This project seeks to better understand links between NF1 and autism. 

This study combines the power of accurate and deep clinical and behavioural phenotyping with novel neuroimaging markers and state-of-the-art laboratory protocols, including genomic testing and neuronal modelling using patient-derived induced pleuripotent stem cells (iPSCs). This will allow the team to map causal pathways from gene to neural circuits to symptoms. 

This data will drive the evidence for personalised and targeted clinical trials in NF1 that are directed towards causal mechanisms rather than symptoms.

Current Status: Recruiting

Source of Recruitment: NF Clinic, Database already held by the Institute

Findings Available: No

Overview: 

Unprecedented advances and enhanced application of genomic technologies in health care are driving an explosion in genetic knowledge that is set to transform the face of modern medicine. Unfortunately, while this knowledge is rapidly leading to increased diagnostic power, translation through to therapeutic benefit and improved health outcomes is progressing at a much slower pace. 

The goal of this project is to address this increasing gap for patients affected by Neurofibromatosis Type 1 (NF1) through the development of novel, safe and efficient therapeutic options based on vector-driven genome editing. 

To achieve this goal, we have assembled an accomplished team with the relevant technological and clinical expertise, access to world-class facilities and resources, including NF1 patient samples, as well as unique expertise in the clinical development of gene therapy technologies.

Current Status: Active

Source of Recruitment: Not applicable

Findings Available: No